Fig. 3: Model of oral chronic dosing with escitalopram.
From: Modulation of serotonin transporter expression by escitalopram under inflammation
a Oral dosing paradigm, (i) shows the differences in escitalopram time profiles in the brain after i.p. and oral administration, (ii) shows the increase of escitalopram when the administration is repeated before clearance, and (iii) shows how escitalopram reaches a steady-state after several administrations. b Modeling of brain concentration of escitalopram (i), serotonin (ii), and SERT surface ratio (iii) following an i.p. injection or oral administration of 1.04 mg kg−1 (equivalent to 5 mg human dose, see Methods). Half-lives of the clearance are provided in the panels. c Modeling oral chronic dosing effects on escitalopram (i), serotonin (ii), and SERT surface ratio (iii). Administration is repeated every 8 h (equivalent to human daily dose, see Methods section). Maximum and minimum values of oscillations, as well as the mean accumulated concentration is given in the panels. Results for the 10 mg and 20 mg human doses can be found in the Supplementary Information Information (Figs. S2, S3). Illustrations made with Biorender.com.
